SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease

Ramirez, Alfredo; van der Flier, Wiesje M.; Herold, Christine; Ramonet, David; Heilmann, Stefanie; Lewczuk, Piotr; Popp, Julius; Lacour, André; Drichel, Dmitriy; Louwersheimer, Eva; Kummer, Markus P.; Cruchaga, Carlos; Hoffmann, Per; Teunissen, Charlotte; Holstege, Henne; Kornhuber, Johannes; Peters, Oliver; Naj, Adam C.; Chouraki, Vincent; Bellenguez, Céline; Gerrish, Amy; International Genomics of Alzheimer's Project (IGAP); Alzheimer's Disease Neuroimaging Initiative (ADNI); Heun, Reiner; Frölich, Lutz; Hüll, Michael; Buscemi, Lara; Herms, Stefan; Kölsch, Heike; Scheltens, Philip; Breteler, Monique M.; Rüther, Eckart; Wiltfang, Jens; Goate, Alison; Jessen, Frank; Maier, Wolfgang; Heneka, Michael T.; Becker, Tim; Nöthen, Markus M.

doi:10.1093/hmg/ddu372

SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease

Cerebrospinal fluid amyloid-beta 1-42 (Aβ1-42) and phosphorylated Tau at position 181 (pTau181) are biomarkers of Alzheimer's disease (AD). We performed an analysis and meta-analysis of genome-wide association study data on Aβ1-42 and pTau181 in AD dementia patients followed by independent replic…